VIDEO: Data supports ovarian suppression plus endocrine therapy in HER2-positive breast cancer
Click Here to Manage Email Alerts
In a video interview, Nancy Lin, MD, of Dana-Farber Cancer Institute, talked about an analysis of HERA trial data presented at ESMO Congress.
The study showed the benefit of integrating ovarian function suppression with adjuvant endocrine therapy in premenopausal women with HR-positive, HER2-postive breast cancer.
“I think that we’ve wondered for a period of time, because HER2 therapy is so good, whether we really need to maximize endocrine therapy in our [patients who are HER2-positive] — particularly because maximizing endocrine therapy does come along with side effects,” Lin told Healio. “These data would suggest that in fact the absolute gains are worth a try as far as maximizing endocrine therapy in our higher risk [patients who are HER2-positive].”
Reference:
Collapse
Click Here to Manage Email Alerts